Cochrane review links pharmaceutical industry gifts to increased prescribing

A Cochrane systematic review of 93 studies has found that gifts and payments from pharmaceutical companies to doctors are associated with increased and less appropriate prescribing. The research, which included 82 studies from the United States, indicates that even small incentives, such as company-sponsored meals, correlate with higher prescription rates for the sponsor’s products, including opioids.

The review highlights a marketing apparatus that includes travel expenses, consulting fees, advisory board payments, and visits from sales representatives. Researchers noted that as exposure to these promotional strategies increases, so does the effect on prescribing behavior. The findings suggest that these interactions may lead to more costly prescriptions and undermine independent medical judgment.

Authors of the study, representing researchers from Australia, Canada, the United Kingdom, and the United States, argue that pharmaceutical promotion should be addressed as a commercial determinant of health. They are calling for governments and the medical community to take concrete action to limit industry influence on healthcare providers.